UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases

Lancet neurology, 2011-07, Vol.10 (7), p.649-656

2011

Volltextzugriff (PDF)

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

Scientific reports, 2020-06, Vol.10 (1), p.10381-10381, Article 10381

2020

Volltextzugriff (PDF)

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1075-1084

2016

Volltextzugriff (PDF)

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Lancet neurology, 2014-04, Vol.13 (4), p.353-363

2014

Volltextzugriff (PDF)

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet neurology, 2014-03, Vol.13 (3), p.247-256

2014

Volltextzugriff (PDF)

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet neurology, 2014-10, Vol.13 (10), p.977-986

2014

Volltextzugriff (PDF)

Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system

PloS one, 2014-03, Vol.9 (3), p.e92842-e92842

2014

Volltextzugriff (PDF)

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis

The New England journal of medicine, 2017-06, Vol.376 (22), p.2122-2133

2017

Volltextzugriff (PDF)

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

Lancet neurology, 2014-03, Vol.13 (3), p.257-267

2014

Volltextzugriff (PDF)

Blood Neurofilament Light Chain: The Neurologist’s Troponin?

Biomedicines, 2020-11, Vol.8 (11), p.523

2020

Volltextzugriff (PDF)

Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation

Frontiers in neuroscience, 2021-03, Vol.15, p.654942-654942

2021

Volltextzugriff (PDF)

Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing

Canadian Journal of Neurological Sciences, 2018-09, Vol.45 (5), p.489-503

2018

Volltextzugriff (PDF)

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

The Lancet (British edition), 2007-08, Vol.370 (9585), p.389-397

2007

Volltextzugriff (PDF)

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Lancet neurology, 2013-08, Vol.12 (8), p.756-767

2013

Volltextzugriff (PDF)

Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases

Therapeutic Advances in Chronic Disease, 2016-01, Vol.7 (1), p.18-33

2016

Volltextzugriff (PDF)

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Lancet neurology, 2012, Vol.11 (1), p.33-41

2012

Volltextzugriff (PDF)

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

Annals of neurology, 2013-03, Vol.73 (3), p.341-354

2013

Volltextzugriff (PDF)

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Lancet neurology, 2009-11, Vol.8 (11), p.987-997

2009

Volltextzugriff (PDF)

Assessing the duration of EDSS improvement after a therapy start: A novel approach applied to the long-term extension of the PRISMS study

Multiple sclerosis and related disorders, 2023-11, Vol.79, p.104945-104945, Article 104945

2023

Volltextzugriff (PDF)

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

Multiple Sclerosis Journal, 2010-04, Vol.16 (4), p.503-510

2010

Volltextzugriff (PDF)

Chronic cerebrospinal venous insufficiency and multiple sclerosis

Annals of neurology, 2010-03, Vol.67 (3), p.286-290

2010

Volltextzugriff (PDF)

Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis

Frontiers in immunology, 2018-05, Vol.9, p.834-834

2018

Volltextzugriff (PDF)

The prognostic significance of cerebrospinal fluid in multiple sclerosis

Journal of the neurological sciences, 2009-04, Vol.279 (1), p.21-25

2009

Volltextzugriff (PDF)

1 – 25 von 1.813

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.584)
Mit Volltextzugriff
(1.385)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(847)
EZB Electronic Journals Library
(736)
IngentaConnect
(677)
Journals@Ovid Ovid Full Text
(655)
NUS Single-Journal Subscriptions
(647)
IngentaConnect Journals
(285)
Elsevier ScienceDirect Journals Complete
(276)
Wiley Online Library
(181)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(163)
Wiley Online Library Full Collection 2018
(124)
Ebook Central Perpetual and DDA
(100)
eBooks on EBSCOhost
(99)
SAGE Journals
(88)
Springer Journals
(86)
Nature_系列刊
(82)
JSTOR
(78)
Oxford journals
(64)
Taylor & Francis eBooks A-Z
(54)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(53)
Nexis Uni
(53)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases

Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

Blood Neurofilament Light Chain: The Neurologist’s Troponin?

Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation

Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Assessing the duration of EDSS improvement after a therapy start: A novel approach applied to the long-term extension of the PRISMS study

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

Chronic cerebrospinal venous insufficiency and multiple sclerosis

Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis

The prognostic significance of cerebrospinal fluid in multiple sclerosis

Suchergebnisse filtern